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TWO YEAR OUTCOMES OF “TREAT AND
EXTEND” INTRAVITREAL THERAPY
USING AFLIBERCEPT PREFERENTIALLY
FOR NEOVASCULAR AGE-RELATED
MACULAR DEGENERATION
DANIEL BARTHELMES, MD, PHD,*† VUONG NGUYEN, PHD,† VINCENT DAIEN, MD, PHD,†‡
ANNA CAMPAIN, PHD,† RICHARD WALTON, MSC,† ROBYN GUYMER, MBBS, PHD,§
NIGEL MORLET, MBBS,¶ ALEX P. HUNYOR, MBBS,†** ROHAN W. ESSEX, MBBS,††
JENNIFER J. ARNOLD, MBBS (HONS),‡‡ MARK C. GILLIES, MBBS, PHD† THE FIGHT RETINAL BLINDNESS
STUDY GROUP
Purpose: To report 24-month outcomes of a treat and extend (T&E) regimen using
aﬂibercept in eyes with neovascular age-related macular degeneration.
Methods: This was a database observational study that included treatment-naive eyes
with neovascular age-related macular degeneration tracked by the Fight Retinal Blindness!
outcome registry completing 24 months of sole monotherapy with aﬂibercept treatment
under a T&E regimen between November 1, 2012 and January 31, 2014. Locally weighted
scatterplot smoothing curves were used to display visual acuity outcomes. Main outcome
measures were change in visual acuity at 24 months and number of injections and visits
during the study period.
Results: The study population, identiﬁed by reviewing the database, consisted of 136
eyes from 123 patients completing 24 months of follow-up on aﬂibercept. Mean (SD) age
was 77.2 (7.0) years, 59% were female. Mean visual acuity increased from 61.4 (20/60; SD
17.4) letters at baseline to 67.4 (20/45; SD 17.7) letters at 24 months (+6.0 letters [95%
conﬁdence interval: 3.3–8.5]; P , 0.001). From baseline to 24 months, the proportion of
eyes with visual acuity $70 letters (20/40) increased (40%–58%, P , 0.001) and the pro-
portion of eyes with visual acuity #35 letters (20/200) remained the same (10%; P = 0.547).
Ninety-eight per cent of eyes starting with visual acuity $70 letters (20/40) were able to
maintain this up to 24 months. From the ﬁrst to the second year of treatment, the mean
number of injections (7.8 [2.1] vs. 5.7 [2.6]; P , 0.001) and visits (8.7 [1.7] vs. 6.5 [2.4]; P ,
0.001) decreased for eyes completing 24 months of treatment. When data from 60 eligible
eyes that did not complete 2 years follow-up, along with 14 eyes that switched to ranibi-
zumab, were included using last observation carried forward, the mean change in visual
acuity from baseline was +5.6 letters (95% conﬁdence interval: 3.3–7.7).
Conclusion: These data indicate that eyes treated with aﬂibercept, as a sole therapy, in
routine clinical practice with a T&E regimen can achieve good visual outcomes while
decreasing the burden of treatments and clinic visits.
RETINA 0:1–9, 2017
Anti-vascular endothelial growth factor (VEGF)agents have revolutionized the management of neo-
vascular age-related macular degeneration (nAMD).
Pivotal clinical trials demonstrated efﬁcacy in visual
outcomes for aﬂibercept,1 bevacizumab,2 and ranibizu-
mab,3,4 mostly using ﬁxed treatment regimens.5,6
Since ﬁxed, especially monthly, treatment schedules
carry a high burden of treatment, variable treatment
regimens, which are usually based on the activity of
neovascular disease being treated, have evolved. Two
different regimens are commonly used: pro re nata
(PRN) and treat and extend (T&E). In the PRN
1
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approach, anti-vascular endothelial growth factor treat-
ment is given only when signs of activity of the cho-
roidal neovascular (CNV) lesion are observed, whereas
T&E entails treatment irrespective of CNV activity but
at progressively increasing intervals when no evidence
of ongoing disease activity is seen, with the aim of
increasing the interval between treatments without al-
lowing reactivation of the CNV. The Comparison of
AMD Treatments Trials, The Study of Ranibizumab
Administered Monthly or on an As-needed Basis in
Patients With Subfoveal nAMD (HARBOUR) trials
and The Neovascular Age-related Macular Degenera-
tion Database Report 1 showed that good visual results
could be achieved using PRN dosing, yet monthly mon-
itoring was still required—thus reducing the number of
injections but not necessarily the number of clinic vis-
its.2,7–10 The outcomes of “real world” T&E treatment
for nAMD using ranibizumab have been reported to be
comparable with those of ﬁxed dosing, randomized
trials,11–16 but only few data are available on T&E
approaches in nAMD using aﬂibercept. We have pre-
viously reported the 2-year results of over 1,000 eyes
under a T&E regimen, but this did not include any eyes
receiving sole monotherapy with aﬂibercept.11 Here we
report the 24-month real-world evidence of a large
cohort of patients with nAMD from centers located in
Australia, New Zealand, and Switzerland treated by
clinicians using aﬂibercept as a sole therapy in an exclu-
sive T&E regimen.
Methods
Study, Design and Setting
This was an observational study of treatment naive
eyes that had received intravitreal therapy for nAMD
in routine clinical practice and had been tracked in the
Fight Retinal Blindness! (FRB!) outcomes database.17
Brieﬂy, the FRB! system was prospectively designed
to collect data from each clinical visit, including the
number of letters read on a logarithm of the minimum
angle (logMAR) of resolution visual acuity chart (best
uncorrected, corrected, or pin hole); activity of the
CNV, for which a deﬁnition is given on the data entry
screen (activity is deﬁned as new intra- or subretinal
ﬂuid as seen on optical coherence tomography or new
hemorrhage); treatment given, if any; ocular adverse
events; and whether the eye had received prior treat-
ment for nAMD. Participants to the FRB! Project
agreed to report $80% of their patients to avoid re-
porting bias. Treatment decisions and visit schedules
were determined by the treating physician in consul-
tation with the patient, which reﬂects real-world prac-
tice. Institutional ethics approval was obtained from
the Human Research Ethics Committees of the
University of Sydney, the Royal Victorian Eye and
Ear Hospital, the Royal Australian and New Zealand
College of Ophthalmologists and the canton of Zurich.
Ethics committees in Australia and New Zealand
approved the use of “opt out” patient consent. The
research described adhered to the tenets of the Decla-
ration of Helsinki. Data were collected from contrib-
uting practitioners located in Australia, New Zealand,
and Switzerland.
Study Population
For this study, the inclusion criteria required
participants to be treatment naive and have started
and continued on aﬂibercept as a sole treatment for
nAMD under a T&E regimen. Eyes that had fewer
than 3 injections within the ﬁrst 12 months were
excluded from analysis. Practitioners using the FRB!
database were contacted by email to self-report their
treatment approaches every year from 2006 to 2014.
The treatment regimens available for selection were
monthly, PRN, T&E, or a combination of these three.
The FRB! database was reviewed for cases that started
with aﬂibercept between November 1, 2012 and
January 31, 2014. Of the 274 cases identiﬁed, 212
were treated under a physician who indicated that they
treat using a T&E protocol.
The primary analysis was conducted on 24-month
completers, but we also report baseline characteristics
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and outcomes for noncompleters, switchers, and all
eyes as a secondary analysis.
Completers were deﬁned as eligible eyes that
completed 24 months of follow-up. Noncompleters
were deﬁned as eyes not completing 24 months of
follow-up during the study period as of May 27, 2016
when the analysis was conducted, thus allowing at
least 3 to 4 months for a follow-up visit to occur after
the end of the 24-month observation period to ensure
correct classiﬁcation of eyes as completers and non-
completers in case of treatment interval extension. As
an example, an eye entering the study on January 31,
2014 with no visit from January 31, 2016 to May 27,
2016 was considered a noncompleter. Switchers were
deﬁned as having $2 consecutive injections of rani-
bizumab before completing 24 months of follow-up.
In these eyes, only visits and visual acuity measure-
ments until the switch were used. A single injection
of ranibizumab was not considered a switch as other
reasons than actually switching treatments may have
been relevant for example availability of the drug,
unintentional use that is aﬂibercept was to be injected
but ranibizumab was prepared and eventually used,
potentially wrong data entry in the original patient
record.
Results, including visual acuity and treatment out-
comes, are presented for completers unless otherwise
speciﬁed. For completers, visual acuity at 24 months
was taken as the most recent visual acuity reading
within 24 months. When analyzing “all eyes,” includ-
ing completers, noncompleters, and switchers, the last
observation carried forward (LOCF) method was used
for noncompleters and switchers.18
Study Measurements
Patient age (years) and sex, visual acuity in
logMAR letters, lesion size (in micrometers) and type
were recorded at the time of the ﬁrst injection. All
treatments were recorded, along with visual acuity,
CNV lesion activity, and ocular adverse events at each
visit.
Outcome Measures
The primary outcome measure was change in mean
visual acuity over 24 months after initiating treatment.
Secondary outcomes were the mean number of
injections and visits over 24 months; the proportion
of eyes maintained on treatment intervals of 4 weeks, 5
to 6 weeks, 7 to 8 weeks, 9 to 10 weeks, 11 to 12
weeks, 13 to 14 weeks and $15 weeks; the treatment
interval extension after the ﬁrst 3 injections; time and
number of injections to ﬁrst grading of CNV inactiv-
ity, retention rates, and ocular safety.
Statistical Analysis
Descriptive data are described with mean (SD),
median (interquartile range [IQR]), number (%), and
95% conﬁdence interval (CI) where appropriate. Stu-
dents t, Wilcoxon rank-sum, ANOVA, Kruskal–Wallis,
McNemars, Fishers and chi-square tests were used as
appropriate to compare baseline characteristics between
completers, noncompleters, and switchers. Locally
weighted scatterplot smoothing curves were used to
analyze visual acuity throughout the follow-up.19
Median time to inactivation and noncompletion/switch
were calculated using Kaplan–Meier curve analysis.
Treatment intervals were categorized into the following
7 groups: 4 weeks (10–34 days), 5 to 6 weeks (35–48
days), 7 to 8 weeks (49–61 days), 9 to 10 weeks (62–76
days), 11 to 12 weeks (77–90 days), 13 to 14 weeks
(91–104 days), and $15 weeks (.105 days). All
analyses were performed using R version 3.3.1 with the
survival package for Kaplan–Meier analyses.20
Results
From the 343 eyes that started aﬂibercept mono-
therapy between November 1, 2012 and January 31,
2014, 274 cases received a minimum of 3 injections
and 212 treatment-naive eyes were treated under
a physician that had indicated that they use a T&E
protocol. A total of 136 eyes from 123 patients com-
pleting 24 months of follow-up (completers) were
identiﬁed. We also identiﬁed 60 treatment-naive eyes
that met the selection criteria but did not complete 24
months of follow-up (noncompleters) and an addi-
tional 16 eyes that switched to ranibizumab before
completing 24 months of aﬂibercept monotherapy
(switchers). Patients were treated by 12 practitioners
who self-reported as using exclusively a treat and
extend regimen during the study period. There were
2,410 injections given within 24 months for all eyes.
Among subjects classiﬁed as “aﬂibercept completers,”
29 (1.2%) injections of ranibizumab were administered
to 29 eyes. No eye in this group, received more than
one nonconsecutive injection of ranibizumab.
Baseline Characteristics
The baseline characteristics amongst all eyes, com-
pleters, noncompleters, and switchers are summarized
in Table 1. Mean baseline age (SD) was younger
among completers compared with noncompleters
(77.2 [7.0] vs. 80.7 [8.2] years [P = 0.005]), whereas
the mean baseline visual acuity (SD) was greater (61.4
[17.4] letters [20/60] vs. 50.1 [22.5] letters [20/100];
P , 0.001). Completers had more eyes with good
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vision (visual acuity $ 70 logMAR letters [20/40],
40% vs. 25%) and fewer with poor vision (visual acu-
ity # 35 logMAR letters [20/200], 10% vs. 25%)
compared with noncompleters. There was no differ-
ence in lesion size (P = 0.806) or type (P = 0.745)
between completers and noncompleters.
Twenty-Four Months Visual Acuity Outcomes
Mean (SD) visual acuity for completers increased
from 61.4 (17.4) letters (20/60) at baseline to 67.4 (17.7)
letters (20/45; +6.0 letters [95% CI: 3.3–8.5]; P ,
0.001). From baseline to 24 months, the proportion of
eyes with visual acuity $70 letters (20/40) increased
(40%–58%, P , 0.001), whereas the proportion with
visual acuity#35 letters (20/200) remained at 10% (P =
0.547). Ninety-eight per cent of eyes starting with visual
acuity $70 letters (20/40) maintained it 24 months after
initiating treatment. Loss of 3 lines ($15 letters) was
avoided by 93% of eyes. As shown in Figure 1, the
mean visual acuity peaked after about 12 months after
beginning therapy before declining slowly.
Twenty-Four Months Visit and Injection
Frequency Outcomes
There was a mean of 7.8 (2.1) injections received in
the ﬁrst year, reducing to 5.7 (2.6) injections in the
second year for completers. Overall, completers
received a mean of 13.6 (4.2) injections over 24 months
of aﬂibercept treatment. The mean number of visits was
8.7 in the ﬁrst year, 6.5 in the second, and 15.1 over the
24-month follow-up period for completers, which was
slightly greater than the mean number of injections
received. For completers, an injection was received in
92% of visits overall. An injection was received in 96%
of visits when an eye was graded as active, and in 84%
of visits when it was graded as inactive, consistent with
a treat and extend approach. The visits without injection
Table 1. Demographic Characteristics of all Eyes, 24-Month Monotherapy Completers, Noncompleters, and Switchers
Completers NonCompleters Switchers All Eyes P
No. eyes 136 60 16 212
No. patients 123 58 15 195
Female (%) 59 65 75 62 0.377
Mean baseline age (SD),
years
77.2 (7.0) 80.7 (8.2) 80.4 (8.5) 78.4 (7.6) 0.007
Mean baseline VA
(Snellen; SD)
61.4 (20/60; 17.4) 50.1 (20/200; 22.5) 63.2 (20/55; 18.9) 58.3 (20/65; 19.7) ,0.001
VA $ 70 letters (20/40; %) 40 25 44 36 0.097
VA# 35 letters (20/200; %) 10 25 6 14 0.020
Lesion size (median, IQR) 2,532 (1,675–3,800) 2,753 (1,575–3,550) 1950 (1,338–3,330) 2,576 (1,513–3,725) 0.512
Angiographic lesion
Type, %
Occult 59 67 63 61 0.789
Minimally classic 12 10 6 11
Predominantly classic 21 15 13 18
Other 7 7 13 8
Not recorded 2 2 6 2
P-Values presented are testing for differences between completers, noncompleters, and switchers.
Completers include all eyes completing 24 months of aﬂibercept monotherapy.
Noncompleters include eyes that have not yet completed 24 months of follow-up and the last VA recorded.
Switchers include eyes that received $2 injections of ranibizumab before completing 24 months of aﬂibercept monotherapy.
All eyes include completers, noncompleters, and switchers.
VA, visual acuity.
The signiﬁcance level is 0.05. The bold values indicate a statistically signiﬁcant difference.
Fig. 1. Locally weighted scatterplot smoothing curve showing the
mean visual acuity for eyes completing 24 months of follow-up.
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were unrelated to the T&E schedule because some pa-
tients in this study had postinjection irritation or came
for a check-up, hence the difference to a perfect T&E
wherein 100% of visits injections would have been
given.
Most (76%) eyes were treated at 4 weekly intervals
for the ﬁrst 3 months. From 4 to 6 months after the ﬁrst
visit, 34% of eyes had been extended to a 6-weekly
and 34% to an 8-weekly interval. At 12 months, 25%
had been extended to an interval of 9 weeks or greater.
By 24 months, 24% of eyes were being treated at an
interval of 12 weeks or greater (4%; Figure 2).
The median injection interval for the ﬁrst 3
injections was 28 days, increasing to 49 days for the
fourth injection. Most eyes were extended by either 2
to 4 weeks (31%) or less than 2 weeks (43%) for the
fourth injection. The remaining eyes were extended for
longer than 4 weeks, with 7% being extended by 2
months after the ﬁrst 3 injections. An overview of
treatment intervals is given in Table 2.
For the subset of completers, 72 (53%) eyes were
treated at 4 weeks intervals for the ﬁrst 3 injections.
The median (IQR) injection interval was 28 (28–32)
days between the ﬁrst and second injections, and 29
(28–42) days between the second and third injections.
First Recorded Grading of Inactivity
The median time and number of injections to ﬁrst
recorded inactive CNV grading was 71 days (IQR 31–
221) and 3 injections (IQR 2–4), respectively. Most
eyes (82%) became inactive within the ﬁrst year, with
only 10% remaining active at the end of 24 months
follow-up (Figure 3). For the eyes that became inac-
tive, 68% required 3 or fewer injections to become
inactive.
Outcomes in Noncompleters
The proportion of eyes not completing 24 months of
follow-up during the study period was 60 out of the
212 eligible eyes (28%). Mean visual acuity change
when eyes were lost to follow-up was +3.9 letters
(95% CI: 21.1 to 8.9) and did not differ between
completers and noncompleters (P = 0.477). Median
(IQR) time to loss of follow-up was 394 days (239–
577 days; Figure 4). Noncompleters received a mean
(SD) of 7.8 (4.0) injections over 9.3 (4.6) visits until
loss to follow-up.
Outcomes in Switchers
The proportion of eyes switching treatments before
completing 24 months of follow-up was 16 out of the
212 eligible eyes (8%). Mean visual acuity change at
time of switching was 7.9 letters (95% CI: 3.0–12.8)
and did not differ between completers and switchers
(P = 0.451). Interestingly, eyes that switched treatment
had higher baseline visual acuity, a higher proportion
with good vision ($70 logMAR letters; 20/40), and
a lower proportion with poor vision (#35 logMAR
letters; 20/200). Median (IQR) time to switching was
169 days (91–376 days; Figure 5). Switchers received
a mean (SD) of 6.6 (3.3) injections over 6.7 (4.1) visits
of aﬂibercept until switching to ranibizumab.
Outcomes in All Eyes
Visual outcomes for all eyes, that is completers,
noncompleters, and switchers, are shown in Table 3.
When noncompleters and switchers were included
using last observation carried forward, the mean
change in visual acuity from baseline was +5.6 letters
(95% CI: 3.3–7.7).
Ocular Safety
Over the course of the study period, 10 adverse
events resulting from 2,415 injections were observed
in all eyes, including noncompleters and switchers: 2
eyes had hemorrhage reducing best-corrected visual
acuity by .15 letters, and 3 eyes had retinal pigment
epithelium tears.
Discussion
We report herein 24-month outcomes of a real-life
cohort of patients with nAMD receiving aﬂibercept as
Fig. 2. Percentage of eyes and their mean treatment interval during
various periods since beginning aﬂibercept monotherapy for com-
pleters.
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a sole treatment under a treat and extend regimen. Two
years after starting therapy, we found a mean gain of
+6.0 logMAR letters in a selected cohort treated in
routine clinical practice. The number of eyes with
good vision ($20/40) increased from 40% to 58%
and 98% of eyes starting with a visual acuity of
$70 letters (20/40) maintained this level. In 93% of
eyes a loss of $15 logMAR letters was avoided.
Ever since anti-vascular endothelial growth factor
drugs became available to treat nAMD, clinicians
have been trying to ﬁnd ways to deliver the optimal
treatment for an individual patient whilst minimizing
the burden of treatment and potential side effects.
Due to its earlier availability, information is now
available on the outcomes of PRN and T&E regimens
using ranibizumab for nAMD in routine clinical prac-
tice.16 Although no direct comparison between PRN
and T&E has been published, it seems that T&E with
ranibizumab may result in better outcomes than
PRN.16
Aﬂibercept for nAMD was initially studied in the
vascular endothelial growth factor Trap-Eye: Investi-
gation of Efﬁcacy and Safety in Wet AMD studies
(VIEW) randomized clinical trial.21 In VIEW, a ﬁxed
treatment was mandated during the ﬁrst year only and
after this a “capped PRN” approach was used.21 The
VIEW study reported a maximum gain of visual acuity
at 52 weeks (ﬁxed treatment phase) followed by a slow
decline in visual acuity thereafter. The VIEW study
found a mean gain in visual acuity of +8 letters in
a cohort that included noncompleters using last obser-
vation carried forward.
Randomized clinical trials usually have strict entry
criteria and a deﬁned protocol on how and when
treatment is to be given. Patients from real world
practice may not always ﬁt these entry criteria but still
receive treatment. Lower or higher mean visual acuity
at start of therapy can lead to bias as eyes with lower
visual acuity have a higher potential to gain visual
acuity, whereas eyes with a relatively high visual
Table 2. Treatment Intervals During the 24-Month Study Period
4 Weeks,
%
5–6 Weeks,
%
7–8 Weeks,
%
9–10 Weeks,
%
11–12 Weeks,
%
13–14 Weeks,
%
15+ Weeks,
%
0–3 Months 76 21 2 0 0 0 0
4–6 Months 18 34 34 9 1 2 2
7–12 Months 12 37 26 15 5 2 3
13–24 Months 12 32 19 14 13 5 6
Overall
Percentage
23 32 20 12 7 3 4
Four weeks, 10–34 days; 5–6 weeks, 35–48 days; 7–8 weeks, 49–61 days; 9–10 weeks, 62–76 days; 11–12 weeks, 77–90 days; 13–14
weeks, 91–104 days; 15+ weeks, .105 days.
Fig. 3. Kaplan–Meier survival analysis of length of time to ﬁrst inac-
tivation of choroidal neovascularization for completers. Fig. 4. Kaplan–Meier survival analysis of length of time to dropout.
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acuity have little chance of gaining more but have
greater potential to lose vision.10,22
Loss to follow-up may bias in favor of a treated
group if the patients who drop out have poorer vision.
Approximately, 36% of eyes did not complete 24
months of aﬂibercept monotherapy in the cohort we
studied. Of these, 28% (60 of 212 eyes) did not
complete the 24-month follow-up and 8% (16 of 212
eyes) switched to ranibizumab. Although noncomp-
leters had a lower proportion of eyes with visual acuity
$70 logMAR letters (20/40) at baseline, a higher pro-
portion of eyes with visual acuity#35 logMAR letters
(20/200), and a lower mean visual acuity (Table 1), an
analysis of all eyes using a last observation carried
forward method did not show a signiﬁcant reduction
in mean outcomes (5.6 gain in all eyes vs. 6.0 letter
gain in completers; Table 3). Noncompleters had sim-
ilar proportions of eyes with a $10 letter loss or gain
and a $15 letter loss at the time of dropping out
compared with completers after 24 months. At the
time of their last recorded visit, mean visual acuity
gain of noncompleters was +4 letters. This suggests
that most eyes that dropped out did not do so due to
poor visual outcomes but other reasons. Similarly, the
16 eyes that switched treatment seemed to have had
a good visual acuity response to treatment at the time
of the switch, with a high proportion of eyes with good
visual acuity at baseline and a gain of 7.4 logMAR
letters when treatments were switched. As reasons for
noncompletion and for switching treatments were not
recorded, it is purely speculative why noncompletion
and switching occurred.
A direct comparison of T&E outcomes from real
world practice between aﬂibercept and ranibizumab
is difﬁcult. Two prospective trials using a T&E
approach and ranibizumab reported 24-month out-
comes of a mean gain in visual acuity from +8 and
+10 logMAR letters.14,15 This is comparable to the
results of current study. The mean baseline visual acu-
ity of these studies was 51 logMAR letters (20/100)15
and 60 logMAR letters (20/60), respectively,14 that is
similar to the current analysis (Table 1). Although
baseline visual acuity is a strong predictor for ﬁnal
visual acuity,10,11 outcomes with respect to mean gain
in visual acuity are comparable.
We have previously published real world outcomes
from a large cohort of nearly 1,200 eyes where
ranibizumab (and to a lesser extent bevacizumab and
aﬂibercept) was used in a T&E approach for treatment
of nAMD.11 Mean visual acuity gains were +5.3 log-
MAR letters at 24 months for eyes completing 24
Fig. 5. Kaplan–Meier survival analysis of length of time to switching.
Table 3. Visual Outcomes for All Eyes, 24-Month Monotherapy Completers, Noncompleters, and Switchers
Completers Noncompleters Switchers All Eyes
No. eyes 136 60 16 212
Baseline VA, mean (Snellen; SD) 61.4 (20/63; 17.4) 50.1 (20/100; 22.5) 63.2 (20/55; 18.9) 58.3 (20/65; 19.7)
Final VA, mean (SD) 67.4 (20/47; 17.7) 54.0 (20/83; 24.6) 70.6 (20/50; 13.2) 63.9 (20/53; 20.6)
DVA (95% CI) 6.0 (3.3 to 8.5) 3.9 (21.1 to 8.9) 7.4 (2.7 to 12.0) 5.6 (3.3 to 7.7)
Gain $10 letters, n (%) 48 (35) 23 (38) 5 (31) 76 (36)
Loss $10 letters, n (%) 15 (11) 9 (15) 0 (0) 24 (11)
Avoid $15 letters loss, n (%) 126 (93) 54 (90) 16 (100) 196 (93)
VA $70 (20/40; baseline/ﬁnal), % 40/58 25/42 44/69 36/54
VA #35 (20/200; baseline/ﬁnal), % 10/10 25/23 6/6 14/13
Injections, mean (SD) 13.6 (4.2) 7.8 (4.0) 6.6 (3.3) 11.4 (5.1)
Visits, mean (SD) 15.1 (3.7) 9.3 (4.6) 6.7 (4.1) 12.8 (5.0)
Completers include all eyes completing 24 months of aﬂibercept monotherapy.
Noncompleters include eyes that have not yet completed 24 months of follow-up and the last VA recorded.
Switchers include eyes that received $2 injections of ranibizumab before completing 24 months of aﬂibercept monotherapy.
All eyes include completers, noncompleters, and switchers.
VA, visual acuity.
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months of treatment. Mean visual acuity at baseline in
that analysis on ranibizumab was 57 logMAR letters
(20/70). The current visual acuity results using aﬂiber-
cept are slightly better, with a mean gain in visual
acuity in completers of +6.0 logMAR letters, however,
this cohort was treated at a later time than the study of
ranibizumab eyes, which was conducted on eyes start-
ing treatment from 2007 to 2012.11 A steady improve-
ment in 24 months outcomes over time for the
ranibizumab eyes was observed (+2.7 letters for 9.7
injections over 24 months to +7.8 letters for 14.2 in-
jections, respectively) in that study, suggesting a poten-
tial learning effect of clinicians. The current data add
to the growing literature on the T&E regimen, which
has hitherto been predominantly on treatment with
ranibizumab. We found that good outcomes can also
be achieved using aﬂibercept in real world practice.
Although there does not seem to be a great differ-
ence in 24-month visual acuity outcomes between
aﬂibercept and ranibizumab, there may have been
a difference in treatment intervals. During the second
year of treatment, only 12% of eyes treated with
aﬂibercept were still on 4-weekly treatments, com-
pared with 19% for ranibizumab.11 Eyes on aﬂibercept
were also treated at somewhat longer intervals during
the second year, with 37% of eyes treated .8 weeks
compared with 34% of eyes using ranibizumab. Again,
the fact the studies were conducted on patients being
treated during different periods of time over which
treatment approaches have very likely changed sug-
gests that comparisons may not be valid.
This analysis has several strengths and limitations.
Observational studies provide data that reﬂect the
ability of a drug to achieve its intended purpose in
the real world. Although the quality of data in
observational studies may be variable, the FRB!
system includes quality assurance measures that
identify out of range and missing data.17
Factors such as preferences for a certain drug in
a particular situation cannot be accounted for, and
reasons for switching treatments. All of the clinicians
participating to the current analysis were established
retina specialists and are experienced in nAMD
treatment. Patients were not, however, randomly
assigned to receive aﬂibercept as they would have
been in a randomized clinical trial. Aﬂibercept may
have been preferred over ranibizumab, which was also
freely available, in some eyes. It has been suggested,
for example, that large retinal pigmented epithelium
detachments, which were not speciﬁcally evaluated at
baseline, may respond well to aﬂibercept.23 Our recent
analysis has revealed that choice of treatment patterns
of ranibizumab and aﬂibercept amongst the practi-
tioners participating in this study have been very
similar since aﬂibercept became available, indicating
that there is no perceived superiority of one drug over
the other.24
Our study provides evidence that is complementary
to the ﬁndings of randomized clinical trials. Overall
we found that a T&E approach using aﬂibercept for
nAMD can produce good outcomes in routine clinical
practice.
Key words: age-related macular degeneration, aﬂi-
bercept, treat and extend, neovascular, CNV, choroidal
neovascularization.
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